Viewing Study NCT00620204


Ignite Creation Date: 2025-12-24 @ 7:50 PM
Ignite Modification Date: 2025-12-25 @ 5:26 PM
Study NCT ID: NCT00620204
Status: UNKNOWN
Last Update Posted: 2009-04-06
First Post: 2008-02-10
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Efficacy Study of Atorvastatin to Treat Variant Angina
Sponsor: Samsung Medical Center
Organization:

Study Overview

Official Title: Efficacy Study of Atorvastatin to Treat Variant Angina
Status: UNKNOWN
Status Verified Date: 2009-04
Last Known Status: RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: ESAVA
Brief Summary: The objective of this study is to evaluate effect of statin treatment for vasospastic angina.
Detailed Description: Vasospastic angina is presented by myocardial ischemia with spasm of coronary artery accompanying chest pain or discomfort. The precise mechanisms have not been established, but a reduction in NO (nitric oxide) production, an imbalance between endothelium-derived relaxing and contracting factors,or an injury of endothelium have been suggested.

Impaired FMD(flow mediated endothelium-dependent vasodilation) in the brachial artery was demonstrated in vasospastic angina,and improvement of endothelial dysfunction with treatment of statin is documented in several studies.

So, we expect that statin treatment for vasospastic angina provide additional therapeutic effects via improvement of endothelial dysfunction.

Study Oversight

Has Oversight DMC: False
Is a FDA Regulated Drug?: None
Is a FDA Regulated Device?: None
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: